For over 50 years, anticoagulant warfarin was the only medication available to combat the risk of blood clots in patients who suffer from atrial fibrillation. Fast forward to 2011 when the FDA approved Bayer Healthcare and Janssen Pharmaceuticals’ drug Xarelto, which was marketed as being superior to warfarin since patients taking Xarelto don’t have to constantly monitor their blood like those who use warfarin. However, the risks associated with Xarelto may far outweigh the benefits. For instance, if a patient suffers a severe bleed due to over-thinning of the blood, warfarin-users can stop the bleeding with a dose of vitamin K to help with clotting while Xarelto-users currently have no such available antidote, which may lead to a fatal bleed.
Numerous lawsuits have been filed against Janssen for its misrepresentation of Xarelto and the bleeding risks it carries. If you or a loved one took Xarelto and suffered internal bleeding or a related medical condition, please call 888-207-0382 for a confidential evaluation of your potential claim.